Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, study suggests

Дата публикации: 27-09-2026 22:10:01

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, makes a case for extending the indication for GLP-1 receptor agonists (GLP1-RAs) to millions more people to protect their heart health.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Daily pill could offer alternative to insulin injections for diabetes patients at cardiovascular risk	0	6.3	30-09-2026
2	Expert: New wave of weight-loss medications	0	14.19	09-09-2026
3	Speaker: GLP-1s may be anti-inflammatory ‘even without obesity’	0	10.61	20-09-2026
4	New evidence supports possible anticancer effects with GLP-1s	0	9.55	18-09-2026
5	Двойной эффект. Как препараты для снижения веса и сахара защищают сердце	0	6.47	01-10-2026
6	EU launches first Screening Week to help detect heart and diabetes risks earlier	0	3.91	29-09-2026
7	Medicare expands availability for GLP-1 weight loss drugs. A KU doctor explains what to know	0	7.53	29-07-2026
8	The GLP-1 Debate Hits Pro Sports	0	12.8	15-09-2026
9	GLP-1 Drugs Not the Most Effective Treatment for Obstructive Sleep Apnea	0	9.78	25-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 7.86. Источник: medicalxpress.com.